Journal of Dermatological Treatment

Papers
(The H4-Index of Journal of Dermatological Treatment is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Minoxidil: a comprehensive review75
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study58
Melasma treatment: a systematic review44
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study43
Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response39
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study34
Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia32
Dupilumab for the treatment of adult atopic dermatitis in special populations30
JAK inhibitors in lichen planus: a review of pathogenesis and treatments26
Topical corticosteroid withdrawal (‘steroid addiction’): an update of a systematic review25
A comprehensive review of platelet-rich plasma for the treatment of dermatologic disorders25
Beneficial effect of Lactobacillus plantarum IS-10506 supplementation in adults with atopic dermatitis: a randomized controlled trial25
Finasteride for hair loss: a review24
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase 24
Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?24
Cosmetic skin lightening use and side effects23
Antifungal resistance in superficial mycoses23
Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment22
Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis22
Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors20
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population20
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials20
0.054066896438599